What Is Leu-Enkephalin? Definition and What Research Reports

Definition

Leu-enkephalin (leucine-enkephalin) is an endogenous opioid pentapeptide — a chain of five amino acids with the sequence Tyr-Gly-Gly-Phe-Leu. It is one of the two classical enkephalins, the other being Met-enkephalin (Tyr-Gly-Gly-Phe-Met), which differs only at the fifth residue. Both are produced in the body by enzymatic processing of a larger precursor protein called proenkephalin, and both act at opioid receptors, particularly the delta and mu subtypes. In the scientific literature the name is written various ways — Leu-enkephalin, leu-enkephalin, [Leu⁵]-enkephalin, or LE — but all refer to the same molecule. It is classed as a neuropeptide and a neurotransmitter/neuromodulator rather than a hormone in the conventional sense.

Where It Comes From

Leu-enkephalin is not synthetic in origin: it is a naturally occurring product of the enkephalin precursor gene. Work on the evolutionary origin of the enkephalins cloned proenkephalin from the Australian lungfish and examined how Met-enkephalin and Leu-enkephalin sequences are arranged within the precursor in lobe-finned fish, a lineage relevant to the evolution of tetrapods (PMID 10960597). That line of research places the peptide among the most evolutionarily conserved signalling molecules in vertebrates.

In humans, enkephalin-containing neurons are distributed widely. An anatomical study mapped the topography of Leu-enkephalin neuronal systems in the human diencephalon and described their associations with luteinizing hormone-releasing hormone (LHRH) neuronal systems, reporting close spatial relationships between the two populations (PMID 12679482). Enkephalins are also measurable in plasma; a clinical study measured plasma Met-enkephalin, beta-endorphin and Leu-enkephalin levels in patients with hepatic encephalopathy and compared them with controls (PMID 17684846).

How the Term Is Used in Peptide Research

In laboratory literature, "Leu-enkephalin" appears in several distinct contexts, and the meaning shifts slightly depending on which one is in play:

• As an endogenous ligand. Studies describe it as a natural agonist at delta and mu opioid receptors, used as a reference compound in receptor binding and functional assays.
• As an anatomical marker. Immunostaining for Leu-enkephalin is used to map peptidergic neurons and fibre systems in brain tissue (PMID 12679482).
• As a biomarker measured in plasma. Circulating levels have been quantified in clinical populations (PMID 17684846).
• As a medicinal-chemistry scaffold. Because the native pentapeptide is short-lived, a large body of work builds modified analogues on the Tyr-Gly-Gly-Phe-Leu backbone to study structure–activity relationships.
• As a model peptide in biophysics. Its small size makes it convenient for studying peptide–membrane interactions; one study investigated the interaction of Leu-enkephalin with lipid membranes (PMID 16542826).

What the Published Literature Reports

This page is for educational purposes only and is not medical advice; consult a licensed physician for any questions about health, medicines or research compounds. Nothing below describes a protocol, and no human dosing is described.

Receptor activity and analogue chemistry

A recurring theme is that the unmodified peptide is rapidly broken down by enkephalin-degrading enzymes, which has driven chemical modification. Researchers synthesised N-guanidyl and C-tetrazole Leu-enkephalin derivatives and reported that these compounds acted as mu and delta opioid receptor agonists with improved pharmacological properties relative to the parent peptide (PMID 30614675). Separate fluorine-chemistry work produced Leu-enkephalin peptidomimetics in which an amide bond was replaced by a trifluoromethylalkene as an "amide isopolar mimic" (PMID 31061541), and a related study reported that a Tyr¹-ψ[(Z)CF═CH]-Gly² fluorinated peptidomimetic improved distribution and metabolism properties compared with Leu-enkephalin (PMID 29648788).

More recently, a 2024 chemistry paper described stapling Leu-enkephalin analogues with bifunctional reagents and reported prolonged analgesic activity for the stapled constructs in its animal testing (PMID 38356394). These are preclinical chemistry studies; they describe molecules in development, not approved therapies.

Enzymatic degradation and potentiation

Because degradation limits the native peptide's duration, some studies have combined it with peptidase inhibitors. One study reported that spinorphin, an endogenous inhibitor of enkephalin-degrading enzymes, potentiated Leu-enkephalin-induced anti-allodynic and antinociceptive effects in mice (PMID 11829145). That result is often cited as evidence that the short in vivo activity of the natural peptide reflects enzymatic breakdown rather than weak receptor engagement.

Non-opioid analogues

Not every Leu-enkephalin-derived molecule is studied for opioid receptor signalling. An animal study examined neonatal administration of non-opiate analogues of Leu-enkephalin and reported effects on heart tissue homeostasis in prepubertal albino rats exposed to hypoxia (PMID 35737163). This illustrates that the enkephalin backbone has been used as a starting point for compounds explored for non-analgesic endpoints in rodents.

Quick Reference Table

Safety and Tolerability: What Studies Report

The verified literature summarised here is largely chemistry, anatomy and preclinical pharmacology, and the abstracts cited do not report a structured human adverse-event profile for Leu-enkephalin. The analogue papers reported pharmacological properties — receptor agonism, distribution and metabolism, and duration of analgesic activity in animal models — rather than tolerability outcomes in people (PMID 30614675, PMID 29648788, PMID 38356394). As a class, opioid receptor agonists carry well-documented risks that are evaluated drug by drug in clinical trials; none of the verified papers above constitutes such a trial for this peptide. Readers assessing safety should look to primary sources and to a licensed clinician rather than to summaries.

Common Points of Confusion

1. Leu-enkephalin vs. Met-enkephalin. They differ by a single C-terminal residue (leucine vs. methionine) and both derive from proenkephalin; both were measured alongside beta-endorphin in one clinical plasma study (PMID 17684846).
2. Leu-enkephalin vs. its analogues. Much of the recent literature concerns modified derivatives — guanidyl/tetrazole, fluoroalkene and stapled versions — not the native peptide (PMID 31061541).
3. Endogenous presence vs. administered compound. Every human carries enkephalins; that fact says nothing about what happens when a related molecule is administered, which is what the preclinical studies set out to test.

References

• Plasma met-enkephalin, beta-endorphin and leu-enkephalin levels in human hepatic encephalopathy (Eastern Mediterranean Health Journal, 2007)
• N-Guanidyl and C-Tetrazole Leu-Enkephalin Derivatives: Efficient Mu and Delta Opioid Receptor Agonists with Improved Pharmacological Properties (ACS Chemical Neuroscience, 2019)
• Spinorphin, an endogenous inhibitor of enkephalin-degrading enzymes, potentiates leu-enkephalin-induced anti-allodynic and antinociceptive effects in mice (Japanese Journal of Pharmacology, 2001)
• Stapling of leu-enkephalin analogs with bifunctional reagents for prolonged analgesic activity (Chemical Communications, 2024)
• Topography and associations of leu-enkephalin and luteinizing hormone-releasing hormone neuronal systems in the human diencephalon (Journal of Clinical Endocrinology and Metabolism, 2003)
• Synthesis of Leu-Enkephalin Peptidomimetics Containing Trifluoromethylalkenes as Amide Isopolar Mimics (Journal of Fluorine Chemistry, 2019)
• Tyr(1)-ψ[(Z)CF═CH]-Gly(2) Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin (ACS Chemical Neuroscience, 2018)
• Deciphering the origin of Met-enkephalin and Leu-enkephalin in Lobe-finned fish: cloning of Australian lungfish proenkephalin (Brain Research, 2000)
• Investigation of interaction of Leu-enkephalin with lipid membranes (Colloids and Surfaces B: Biointerfaces, 2006)
• Effects of Neonatal Administration of Non-Opiate Analogues of Leu-Enkephalin to Heart Tissue Homeostasis of Prepubertal Albino Rats Exposed to Hypoxia (Bulletin of Experimental Biology and Medicine, 2022)